## **European Respiratory Society Annual Congress 2013**

**Abstract Number: 2771** 

**Publication Number:** P2911

Abstract Group: 11.1. Lung Cancer

Keyword 1: Lung cancer / Oncology Keyword 2: No keyword Keyword 3: No keyword

**Title:** Prognostic value study of lung cancer molecular markers and value of mitochondrial activity in resected non-small cell lung cancer

Dr. Rodrigo 21960 Alonso Moralejo isildur77@yahoo.com MD ¹, Dr. Javier 21961 Pinillos Robles ejpr1@hotmail.com MD ¹, Dr. Ricardo 21962 Garcia Lujan rglujan@hotmail.com MD ¹,², Dr. Carlos 21963 Alvarez Martinez carlosjose.alvarez@salud.madrid.org MD ¹,² and Dr. Angel 21964 Lopez Encuentra lencuent@h12o.es MD ¹. ¹ Pneumology Service, Hospital Universitario 12 De Octubre, Madrid, Spain, 28041 and ² CIBERES, Hospital Universitario 12 De Octubre, Madrid, Spain .

**Body:** Aim:Determine the prognostic value of molecular markers (MM) of different lung cancer paths, and the value of mitochondrial activity (MA) in resected non small cell lung cancer (NSCLC). Method:Observational, cohort study in patients with resected NSCLC in our hospital in a four year period. 32 MM were selected. The study consisted on the elaboration of tissue arrays with samples from resected tumor, using a semiquantitative immunohistochemical study. The expression of 4 MA proteins were studied, β-F1-ATPase, Hsp60, GAPDH and PK by inmunohistochemical analysis. For each one of the markers the possible results were established according to intensity and percentage of cells that expressed the protein and the result of multiplying both values. A prognosis analysis was done with the expression of each protein and the overall 5-year survival rate was calculated. Results:134 patients were studied, 92% were men, with mean age of 66.8 (SD: 8), with a 66% of squamous tumors. The results are summarized in the table

## Molecular marker and probability of survival

| Molecular marker | Molecular expression | n   | Probability of survival in 5 years | Wilcoxon | Log rank |
|------------------|----------------------|-----|------------------------------------|----------|----------|
| p16B             | Negative             | 117 | 0.50                               | 0.011    | 0.017    |
|                  | Positive             | 16  | 0.25                               |          |          |
| P27              | Negative             | 84  | 0.54                               | 0.082    | 0.054    |
|                  | Positive             | 44  | 0.34                               |          |          |
| RB               | Negative             | 34  | 0.32                               | 0.026    | 0.048    |
|                  | Positive             | 98  | 0.54                               |          |          |
| Fas              | Negative             | 118 | 0.47                               | 0.06     | 0.061    |
|                  | Positive             | 10  | 0.70                               |          |          |
| β-F1-ATPasa      | Low and moderate     | 56  | 0.36                               | 0.07     | 0.14     |

| Strong | 72 | 0.53 |  |
|--------|----|------|--|

Conclusions:We found two MM with long-term prognostic value. The expression of MA proteins doesn't have significant prognosis value in our population. The cases with strong expression of  $\beta$ -F1-ATPasa have a longer survival, which is clinically relevant. Supported by a research grant SEPAR 817/2009.